February 15, 2012
The A-Z’s of multiple sclerosis, explained
- /
Multiple Sclerosis, a nervous system disorder, can lead to a host of problems such as muscle weakness, memory complications, trouble…
MS Views and News, empowers those affected by Multiple Sclerosis (MS) with educational information, resources and services. Please scroll downward to find articles or videos of interest, then click to open the document or video.
February 15, 2012
Okay we already know that smoking is bad for you. But with MS it is even worse
- /
- /
http://www.nationalmssociety.org/Research-2005Apr28-2.asp NMSS study on smoking and progression http://www.nationalmssociety.org/Sourcebook-Smoking.asp Info on smoking from the NMSS Sourcebook http://www.medscape.com/viewarticle/503872?src=mp Smoking may…
February 14, 2012
Daclizumab Use in Patients With Pediatric Multiple Sclerosis
- /
- /
Mark P. Gorman, MD; Jan-Mendelt Tillema, MD; Annika M. Ciliax, MD; Charles R. G. Guttmann, MD; Tanuja Chitnis, MD Arch Neurol. 2012;69(1):78-81. doi:10.1001/archneurol.2011.581 Background Daclizumab,…
February 14, 2012
Social Security Expands Compassionate Allowances List
- /
Posted by Doug LandauFebruary 14, 2012 From Stuart: Some of the wording baffles me in the article found below, like Malignant…
February 14, 2012
Commentary: Environmental, genetic factors play roles in getting MS
- /
By James Winkley — Special to the Herald-Leader Posted: Feb 13, 2012 When I tell a patient he or she has…
February 14, 2012
An MS Patient’s Story – Swept off my feet by the smart, sweet, gentle, handy man
- /
- /
Column by Joan Herman / For The Daily News | Posted: Monday, February 13, 2012 For years after my marriage ended, I dated…
February 14, 2012
The MS Dream Center of Rhode Island
- /
- /
The MS Dream Center – R.I. is to engage all members with MS in purposeful activity, while promoting a spirit…
February 14, 2012
Immunological Markers of Optimal Response to Natalizumab (Tysabri) in Multiple Sclerosis
- /
- /
Luisa M. Villar, PhD; María I. García-Sánchez, PhD; Lucienne Costa-Frossard, MD; Mercedes Espiño, PhD; Ernesto Roldán, PhD; Dolores Páramo, MD; Miguel Lucas, PhD;Guillermo Izquierdo, …
February 14, 2012
The ALS Therapy Development Institute (ALS TDI) will launch a Phase II clinical trial on TDI 132 (aka: fingolimod/Gilenya(R)) as a potential treatment for ALS (Lou Gehrig’s disease)
- /
Feb 14, 2012 CAMBRIDGE, Mass., Feb. 14, 2012 /PRNewswire-USNewswire/ — The ALS Therapy Development Institute (ALS TDI) will launch a Phase II clinical…
February 14, 2012
A flowering Tibetan shrub that tricks cells into thinking they are starving could become a weapon against multiple sclerosis and even old age
- /
February 13, 2012 The roots of the blue evergreen hydrangea (Dichroa febrifuga) have been used for centuries in traditional Chinese medicine to…
